Coronary disease & ACSCohort study
Development of a Novel BifurcAID Risk Score to Predict Major Adverse Cardiovascular Events (MACE) Following Coronary True Bifurcation Intervention
- Retrospective cohort study
- single-centre
- risk score development
- independent core laboratory
Authors' conclusion
The BifurcAID risk score may facilitate risk stratification among patients undergoing true bifurcation PCI and guide patient-tailored treatment strategies.
Study context
- Population
- Consecutive patients undergoing percutaneous coronary intervention (PCI) for true bifurcation lesions, 2012–2019, single institution
- Participants
- 1,896 consecutive patients
- Exposure
- BifurcAID risk categories: intermediate and high vs low risk
- Outcome
- MACE:
- All-cause death
- MI
- Target vessel revascularization
- Follow-up
- 1 year
Main finding
As reported in the abstract
MACE by risk category
Each group vs low riskOdds ratio (95% CI)P value
Intermediate risk
2.63(1.74–3.98)
P < 0.001High risk
5.18(3.56–7.53)
P < 0.001Observational data: associations, not effects.
Further findings
Overall 1-year MACE
- MACE in 185 patients
- 9.8%
Predictors of MACE
- Clinical predictors: insulin-dependent DM, LVEF ≤30%, NSTEMI presentation, age >80 years, non-white race/ethnicity
- 5
- Angiographic predictors: left main or left circumflex-obtuse marginal lesion, multivessel disease, side branch thrombus, side branch moderate/severe calcium, side branch lesion length >10 mm
- 6
- Eleven predictors in total
Original publication
Development of a Novel BifurcAID Risk Score to Predict MACE Following Coronary True Bifurcation Intervention. JACC Cardiovasc Interv. Published 24 March 2025. doi:10.1016/j.jcin.2024.11.034
Summarised from the published abstract; every number is checked against it